Rilonacept
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Neurosensory Hearing Loss (ANSHL)
Conditions
Autoimmune Neurosensory Hearing Loss (ANSHL)
Trial Timeline
Feb 1, 2017 → Mar 1, 2018
NCT ID
NCT02828033About Rilonacept
Rilonacept is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Autoimmune Neurosensory Hearing Loss (ANSHL). The current trial status is unknown. This product is registered under clinical trial identifier NCT02828033. Target conditions include Autoimmune Neurosensory Hearing Loss (ANSHL).
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Neurosensory Hearing Loss (ANSHL) were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00609544 | Phase 2 | Withdrawn |
| NCT02828033 | Phase 1 | UNKNOWN |
| NCT01538719 | Phase 1/2 | Completed |
| NCT00856206 | Phase 3 | Completed |
| NCT00610363 | Phase 2 | Completed |
Competing Products
20 competing products in Autoimmune Neurosensory Hearing Loss (ANSHL)